Using GnRH agonist for IVF and FET to improve live birth rates
Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer
This study is testing if using a GnRH agonist instead of the usual hCG trigger can help women undergoing IVF have more successful pregnancies and if it can also support women during frozen embryo transfers.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 784 (estimated) |
| Ages | 18 Years to 42 Years |
| Sex | Female |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, Hong Kong) |
| Trial ID | NCT04064840 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effectiveness of a dual trigger approach using GnRH agonist versus traditional hCG trigger in women undergoing in vitro fertilization (IVF). Additionally, it evaluates the efficacy of GnRH agonist for luteal phase support compared to a placebo in women undergoing frozen embryo transfer (FET). The study involves a randomized, double-blinded, and placebo-controlled design, ensuring rigorous assessment of outcomes. Participants will be monitored throughout the IVF process, including ovarian stimulation and embryo culture, to determine the impact on live birth rates.
Who should consider this trial
Good fit: Ideal candidates are women under 43 years of age who are undergoing IVF or FET treatments.
Not a fit: Patients using donor oocytes or embryos, or those with specific medical conditions like hydrosalpinx, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance live birth rates for women undergoing IVF and FET treatments.
How similar studies have performed: Other studies have shown promising results with similar dual trigger approaches in IVF, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
IVF Inclusion criteria: \- Women aged \<43 years at the time of IVF treatment Exclusion criteria: * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated * Women at risk of OHSS FET Inclusion criteria: * Women aged \<43 years at the time of IVF treatment * Replacing early cleavage embryos or blastocysts after thawing * FET in natural cycles Exclusion criteria: * Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated
Where this trial is running
Hong Kong, Hong Kong
- Department of Obstetrics and Gynaecology — Hong Kong, Hong Kong, China (Recruiting)
Study contacts
- Principal investigator: Ernest HY Ng, MD — The University of Hong Kong
- Study coordinator: Ernest HY Ng, MD
- Email: nghye@hku.hk
- Phone: 852-28553400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.